Congress reasserts control over Medicare innovation testing with new oversight rules

What it does

This bill adds guardrails to how the Centers for Medicare & Medicaid Innovation (CMI) tests and expands new payment models. It caps Phase I testing at 5 years and 500,000 beneficiaries, limits CMI to 6 new Phase I models per year, requires hardship waivers for providers, mandates real-time monitoring of patient impacts, and gives Congress a 45-day window to block model expansions via joint resolution. It also restores judicial review of CMI actions (previously barred), requires public notice and 45-day comment periods, and clarifies that models can focus on quality improvements even without guaranteed savings.

Why we flagged it

The bill's core function is to add procedural constraints, transparency requirements, and congressional oversight to CMI's authority to test and expand payment models. It is not deregulation or a carve-out; it is a governance reform that tightens CMI's discretion while protecting beneficiaries and providers.

What the text implies

• The 45-day congressional disapproval window (Section 4) creates a legislative veto mechanism that may face constitutional challenge under the Presentment Clause, though the bill frames it as a procedural rule of each House.
• Requiring CMI to provide actuarial assumptions and data to participating providers (Section 9(d)) may increase transparency but could also enable providers to challenge model terminations or modifications in court, potentially slowing CMI's ability to wind down unsuccessful models.
• The hardship waiver requirement (Section 3(c)) is discretionary ('if the Secretary determines') and lacks a timeline for decisions, creating potential for delays or inconsistent application across providers.
• Restoring judicial review (Section 6) reverses prior immunity language but the carve-out ('except as may be necessary to enforce the requirements of this section or other laws or constitutional provisions intended to protect beneficiaries') may still shield some CMI actions from review.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary Medicare and Medicaid beneficiaries gain procedural protections: real-time monitoring of adverse impacts, hardship waivers for providers, mandatory public notice and comment periods, and restored judicial review. Providers gain transparency into actuarial assumptions and data used to evaluate models. Congress regains oversight via a 45-day disapproval mechanism. The bill does not restrict access or benefits; it adds guardrails to prevent unintended harms from experimental models.

Named in the bill

Centers for Medicare & Medicaid Innovation (CMI), Secretary of Health and Human Services, House Committee on Ways and Means, House Committee on Energy and Commerce, Senate Committee on Finance, Senate Committee on Health, Education, Labor, and Pensions, Chief Actuary of the Centers for Medicare & Medicaid Services, Comptroller General of the United States, Medicare, Medicaid, Social Security Act (Title XI, Section 1115A)

Where it stands

• Oct 1, 2026 — Introduced · Congress.gov: “Introduced in House”
• Oct 1, 2026 — Referred to House Committee on Rules and House Committee on Ways and Means · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.